Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0001641172-25-023970
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Net Income | -$5.07M | -$1.39M | -$1.55M |
| EPS Diluted | -$0.17 | $0.05 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end
